Richard J. Benjamin - Nov 3, 2021 Form 4 Insider Report for CERUS CORP (CERS)

Role
Chief Medical Officer
Signature
Richard J. Benjamin by Chrystal Menard, attorney-in-fact
Stock symbol
CERS
Transactions as of
Nov 3, 2021
Transactions value $
-$514,617
Form type
4
Date filed
11/5/2021, 07:41 PM
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERS Common Stock Options Exercise $472K +100K +131.52% $4.72 176K Nov 3, 2021 Direct
transaction CERS Common Stock Sale -$790K -100K -56.81% $7.90 76K Nov 3, 2021 Direct F1
transaction CERS Common Stock Options Exercise $144K +33.3K +43.84% $4.33 109K Nov 3, 2021 Direct
transaction CERS Common Stock Sale -$245K -33.3K -30.48% $7.35 76K Nov 3, 2021 Direct F1
transaction CERS Common Stock Options Exercise $137K +31.7K +41.65% $4.32 108K Nov 3, 2021 Direct
transaction CERS Common Stock Sale -$233K -31.7K -29.4% $7.35 76K Nov 3, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERS Option (Right to Buy) Options Exercise -100K -100% 0 Nov 3, 2021 Common Stock 100K $4.72 Direct F2, F3
transaction CERS Option (Right to Buy) Options Exercise -33.3K -80% 8.33K Nov 3, 2021 Common Stock 33.3K $4.33 Direct F2, F3
transaction CERS Option (Right to Buy) Options Exercise -31.7K -50% 31.7K Nov 3, 2021 Common Stock 31.7K $4.32 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a 10b5-1 plan.
F2 One eighth (1/8th) of the shares subject to the Option vested six (6) months after the grant date, and one forty-eighth (1/48th) of the shares subject to the Option vested each month thereafter.
F3 Not applicable.